Compare · LUNR vs TMO
LUNR vs TMO
Side-by-side comparison of Intuitive Machines Inc. (LUNR) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUNR and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $177.93B, about 32.4x LUNR ($5.50B).
- Over the past year, LUNR is up 194.7% and TMO is up 14.2% - LUNR leads by 180.4 points.
- LUNR has been more active in the news (12 items in the past 4 weeks vs 9 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 12 for LUNR).
- Company
- Intuitive Machines Inc.
- Thermo Fisher Scientific Inc
- Price
- $25.34+2.16%
- $479.36+2.79%
- Market cap
- $5.50B
- $177.93B
- 1M return
- +36.75%
- -2.51%
- 1Y return
- +194.65%
- +14.23%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 12
- 9
- Recent ratings
- 12
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest LUNR
- SEC Form DEFA14A filed by Intuitive Machines Inc.
- SEC Form DEF 14A filed by Intuitive Machines Inc.
- SEC Form 4 filed by Ghaffarian Kamal Seyed
- As SpaceX Moves Toward a Record-Setting IPO, The Non-SpaceX Space Infrastructure Stack Is Being Repriced -- And One MACH 2+ Air-Launch Operator Is Quietly Stacking Partnerships
- SEC Form 4 filed by Mcgrath Peter
- SEC Form 4 filed by Jones Anna Chiara
- SEC Form 4 filed by Altemus Stephen J
- SEC Form 4 filed by Crain Timothy Price Ii
- Merlin Names Board of Directors Including Former Secretary of the Navy, Amazon's First Chief Accounting Officer, and Former Blue Origin CEO
- SEC Form 144 filed by Intuitive Machines Inc.
Latest TMO
- President & COO Pettiti Gianluca sold $185,064 worth of shares (400 units at $462.66) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 25,051 units (SEC Form 4)
- Thermo Fisher Scientific to Host Investor Day
- Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026